Sanofi to cut 1,700 jobs in U.S. pharma sector
The Paris-based company said the decisions will be finalized in mid-December, and the move will allow the company to better focus on the areas of diabetes, atrial fibrillation and oncology.
"This step in our transformation strategy will expedite decision making, reduce business complexities and increase innovation, ensuring we rapidly respond to patient and customer needs," said Gregory Irace, president and CEO of Sanofi-Aventis U.S./Canada pharmaceutical operations.
Currently, 6,900 people are employed within the company’s pharmaceutical operations division.